Together, these pharmacologic and genetic data suggest that PI3Kα is involved in the reactivation of PI3K signaling after PI3Kδ inhibition in ABC DLBCL cells. The gene discussed is PIK3CD; the disease is diffuse large B-cell lymphoma.